IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10071980 B1

PDFFull Text
Date of Patent:
Sep. 11, 2018

Filed:

Jun. 26, 2015

Agonists that enhanced binding of integrin-expressing cells to integrin receptors

Applicant:

Texas Heart Institute, Houston, TX (US);

Inventors:

Ronald J. Biediger, Houston, TX (US);

Robert V. Market, Houston, TX (US);

Assignee:

TEXAS HEART INSTITUTE, Houston, TX (US);

Attorney:

Conley Rose, P.C.

Primary Examiner:

My-Chau T Tran

Int. Cl.
CPC ...
C07D 333/10 (2006.01); C07D 333/20 (2006.01); C07D 275/02 (2006.01); C07D 409/14 (2006.01); C07C 271/20 (2006.01); C07C 311/08 (2006.01); C07D 213/64 (2006.01); C07D 317/60 (2006.01); A61K 35/17 (2015.01); A61K 35/51 (2015.01); C07D 409/12 (2006.01); C07D 413/14 (2006.01); A61K 35/12 (2015.01); C07C 229/34 (2006.01); C07C 271/22 (2006.01); C07D 333/24 (2006.01);
U.S. Cl.
CPC ...
C07D 333/20 (2013.01); A61K 35/12 (2013.01); A61K 35/17 (2013.01); A61K 35/51 (2013.01); C07C 229/34 (2013.01); C07C 271/20 (2013.01); C07C 271/22 (2013.01); C07C 311/08 (2013.01); C07D 213/64 (2013.01); C07D 275/02 (2013.01); C07D 317/60 (2013.01); C07D 333/10 (2013.01); C07D 333/24 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01);
Abstract

A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

Find Patent Forward Citations

Loading…